RT Journal Article
T1 New Horizons in the Treatment of Corneal Endothelial Dysfunction.
A1 Rocha-de-Lossada, Carlos
A1 Rachwani-Anil, Rahul
A1 Borroni, Davide
A1 Sánchez-González, José-María
A1 Esteves-Marques, Raquel
A1 Soler-Ferrández, Fernando-Luis
A1 Gegúndez-Fernández, Jose-Antonio
A1 Romano, Vito
A1 Livny, Eitan
A1 Rodríguez Calvo-de-Mora, Marina
AB The treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors (ROCK inhibitors), bioengineered grafts, and gene therapy have been described. These techniques represent new lines of treatment for endothelial dysfunction. Their advantages are to help address the shortage of quality endothelial tissue, decrease the complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available alternatives and advancements to endothelial corneal transplant.
SN 2090-004X
YR 2021
FD 2021-07-09
LK http://hdl.handle.net/10668/18259
UL http://hdl.handle.net/10668/18259
LA en
DS RISalud
RD Apr 9, 2025